Do R&D credit carryforwards survive an acquisition?

They survive, but their usability is throttled. After an ownership change — generally a more-than-50-percentage-point shift among 5% shareholders over three years — Section 383 limits annual use of pre-change credit carryforwards by reference to the Section 382 limitation: roughly the target's equity value times the long-term tax-exempt rate, converted to credit-equivalent terms. Large carryforwards on small equity values can take decades to use.

Does a buyer inherit the target's tax exposure from aggressive credit or cost segregation studies?

In a stock deal, yes — the corporation's historic liabilities, including open-year exam risk on prior claims, come along, typically addressed through indemnities, escrows, or tax liability insurance. In an asset deal the entity-level income tax exposure generally stays with the seller, though the buyer takes assets at purchase-price basis and loses the target's attributes entirely.

How does a quality-of-earnings analysis treat tax credits?

Recurring, defensible credits supported by ongoing activity can be treated as a sustainable component of earnings or cash flow; one-time catch-ups — a cost segregation 481(a) adjustment, a retroactive amended-return refund — are normalized out. Diligence teams also haircut credits with weak documentation, since their value depends on surviving exam.

Tax incentives in M&A due diligence

Specialty tax items show up on both sides of a deal ledger. On the asset side: credit carryforwards, unamortized deductions, and studies that will keep generating benefits. On the liability side: open-year exposure from claims that may not survive examination. Diligence's job is to price both — and the three tools it uses are quality-of-earnings normalization, the Section 382/383 attribute limits, and contractual risk allocation for successor exposure.

Quality of earnings: recurring versus one-time

A quality-of-earnings (QoE) analysis asks what the business sustainably produces. A research credit generated annually by a stable engineering organization is arguably a recurring reduction in cash taxes and can support the adjusted-EBITDA or free-cash-flow story — if the documentation supports the claim at the level audit-ready records require. Diligence teams increasingly test this directly: sampling business components against the four-part test, checking whether Form 6765 Section G detail exists, and haircutting credits that rest on interview-based studies.

One-time items get normalized out. A cost segregation catch-up taken through a Section 481(a) adjustment, a retroactive Section 174A refund from amended 2022–2024 returns, an expiring-incentive claim (Section 179D property must begin construction by June 30, 2026) — these are real cash but not run-rate. Deferral items cut the other way: accelerated depreciation already taken means smaller future deductions and built-in recapture, a deferred tax liability a careful buyer models rather than ignores.

Sections 382 and 383: the carryforward throttle

An acquisition of a loss or credit company almost always triggers an ownership change — a more-than-50-percentage-point shift among 5% shareholders within three years. Afterward, Section 382 caps annual use of pre-change NOLs at the target's equity value times the long-term tax-exempt rate (published monthly; in the low-4% range in mid-2026). Section 383 applies the same cap, converted through tax rates, to pre-change credit carryforwards, including research credits.

The arithmetic is sobering. A startup acquired at a $30 million equity value with a 4% rate has a $1.2 million annual 382 limitation; in credit-equivalent terms under 383, that shelters only about $252,000 of credits per year at a 21% rate. A $5 million research credit carryforward would need roughly twenty years — conveniently, the full Section 39 carryforward life — and any shortfall simply expires. Buyers should also test Section 382(l)(4)'s continuity-of-business requirement and remember the limitation compounds with the general credit usability limits under Section 38(c). The practical result: NOL and credit carryforwards are routinely valued in diligence at steep discounts to face, and letters of intent that price them at 100 cents are a tell that no tax diligence has happened yet.

Successor exposure for aggressive studies

Structure decides who holds the history. In a stock acquisition, the target corporation's tax years remain open under the ordinary statute of limitations — three years, six for large omissions — and its exam risk transfers with it. A contingency-fee credit study or an aggressive allocation the seller commissioned two years ago is now the buyer's audit. Standard responses: specific indemnities for identified positions, escrows or holdbacks sized to the exposure, tax liability insurance for quantifiable single issues, and pre-closing voluntary fixes (a Form 3115 to correct a bad method, or withdrawal of a pending refund claim). In an asset deal, historic entity-level income tax stays behind, but so do the attributes — the buyer gets stepped-up basis and no carryforwards, which is often the better trade anyway.

The unifying discipline: value attributes at usable, risk-adjusted present value, and treat every unexamined specialty claim as a contingent liability until the file proves otherwise.